Bloomberg the Company

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Follow Us

Industry Products

  • Exchange: NASDAQ GS
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

OncoMed Pharmaceuticals Inc

+ Add to Watchlist

OMED:US

25.5059 USD 1.2541 4.69%

As of 11:30:34 ET on 02/27/2015.

Snapshot for OncoMed Pharmaceuticals Inc (OMED)

Open: 26.4700 Day's Range: 25.3900 - 26.7600 Volume: 54,367
Previous Close: 26.7600 52wk Range: 16.5700 - 39.4999 1-Yr Rtn: -26.11%

Stock Chart for OMED

No chart data available.
  • OMED:US 25.4600
  • 1D
  • 1M
  • 1Y
26.7600
Interactive OMED Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for OMED

Current P/E Ratio (ttm) -
Estimated P/E(12/2014) -
Relative P/E vs. SPX -
Earnings Per Share (USD) (ttm) -1.3300
Est. EPS (USD) (12/2014) -1.6540
Est. PEG Ratio -
Market Cap (M USD) 798.31
Shares Outstanding (M) 29.83
30 Day Average Volume 150,956
Price/Book (mrq) 8.5169
Price/Sale (ttm) 14.8931
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 03/18/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for OMED

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for OMED

OncoMed Pharmaceuticals, Inc. provides biotechnology research and development. The Company synthesizes oncogenic mutations in stem cells that allows the cells to grow without normal limitations in attempts to exploit therapies that selectively target tumor initiating cells. OncoMed Pharmaceuticals serves the healthcare industry and cancer therapy patients in the United States.

Paul J HastingsChairman/President/CEOJohn A LewickiExec VP/Chief Scientific Ofcr
Sunil PatelSenior VP:Corporate Dev/CFOJakob DupontSenior VP/Chief Medical Ofcr
More Company Profile & Key Executives for OMED

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil